<DOC>
	<DOCNO>NCT00212615</DOCNO>
	<brief_summary>XELOX ( Capecitabine Oxaliplatin ) effective convenient regimen patient metastatic colorectal cancer . Chronomodulated therapy may reduce toxicity . Patients randomized standard XELOX ( Capecitabine 1000 mg/m² morning 1000 mg/m² even day 1-14 short term Oxaliplatin 130 mg/m² day 1 30 minute ) chronomodulated XELOX ( Capecitabine 400 mg/m² morning 1600 mg/m² even day 1-14 short term Oxaliplatin 130 mg/m² day 1 30 minute ) . Bloodsamples collect frozen later examine potential predictive factor</brief_summary>
	<brief_title>XELOX III . Xeloda Combination With Eloxatin Patients With Advanced Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histological proven adenocarcinoma colon rectum Measurable nonmeasurable disease Performance status 02 Adequate renal hepatic function Adjuvant chemotherapy must end 180 day inclusion Written inform consent prior randomization Prior treatment Eloxatin Xeloda Peripheral neuropathy Evidence CNS metastasis Other serious illness medical condition ( include contraindication 5 FU e.g . : angor , myocardial infarction within 6 month ) Past history malignant neoplasm within past five year , except curatively treat non melanoma skin cancer Administration experimental drug investigation within 2 week randomisation Pregnant breast feed woman Fertile patient must use adequate contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Colorectal neoplasm</keyword>
	<keyword>Capecitabine ( Xeloda )</keyword>
	<keyword>Oxaliplatin ( Eloxatin )</keyword>
	<keyword>Advanced disease</keyword>
	<keyword>Metastatic disease</keyword>
	<keyword>First-line treatment</keyword>
	<keyword>Phase II study</keyword>
</DOC>